Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a supplement boost mobility and brain power in frail seniors?

NCT ID NCT06027554

Symptom relief Sponsor: UConn Health Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Aug 13, 2026 · Updated 3 times

Summary

This study tests whether a daily MitoQ supplement for 12 weeks can improve blood vessel function, walking speed, and thinking skills in frail older adults aged 65-80. Researchers will measure changes in blood flow, cognitive tests, and physical performance. The trial involves 60 participants and compares MitoQ to a placebo.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
MitoQ (mitoquinone mesylate) supplement
What this could lead to
If it works, this could point toward a simple supplement to help frail older adults move better and think more clearly.
What could go wrong
This is a small early-phase trial with only 60 people. The supplement may not work better than a placebo, and results may not apply to everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 60 people

The number the study aims to enrol. It can still change while the study runs.

Started

Oct 2024

Expected to finish

Feb 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

65 to 80 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * men and women aged 65-80 with a slow gait speed (0.4m/s based on a 4m walk) and/or mild cognitive impairment. * good cardiovascular health (not taking any blood pressure/flow/metabolism altering medications) Exclusion Criteria: * A vaccination in past two weeks * Recent acute infection three weeks prior to enrollment * Known immunodeficiency (including HIV infection, primary immunodeficiency, any history of chemotherapy or radiotherapy * Use of medicines during past 6 months known to alter immune response such as high- dose corticosteroids * Severe autoimmune disease requiring biological therapy * Major severe illness and/or Hospitalization in past 3 months * On warfarin or other medications that are considered a blood thinner * Recent fall or other conditions that will impair ability to complete and/or interpret mobility performance test * Known bleeding disorder * Any conditions that would impair the function to perform grip strength test * include advanced neurological disease, severe co-morbid disease, terminal illness with reduced life expectancy, severe disability, unintentional weight loss in last 12 months and participation in another study. * Diabetes patients requiring insulin (For reducing the risk that participants will have hypoglycemic episodes when fasting for study visits) * Baseline ECG QTc \>450 ms in men and QTc \>460 ms in women * Prior diagnosis of ventricular arrhythmia (e.g., ventricular tachycardia, ventricular fibrillation, torsades de pointes)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Aging are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Cognitive Dysfunction Frailty

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Aging Frailty Mild cognitive impairment

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • UConn Health

    RECRUITING

    Farmington, Connecticut, 06030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.